Latest research on Darunavir

Darunavir is a protease inhibitor used to treat HIV. It acts on the HIV aspartyl protease which the virus needs to cleave the HIV polyprotein into its functional fragments.

Darunavir dosage

Single doses of Darunavir up to 3200 mg and atazanavir up to 1200 mg have been administered to healthy volunteers with no apparent ill effects [32,33]. [source, 2016]
We identified eight studies comparing the cost-effectiveness analyses of the specific HAART regimens; two compared Darunavir + low-dose Ritonavir (DRV/r) with Lopinavir + Ritonavir. [source, 2015]
The fixed-dose combination emtricitabine/tenofovir disoproxyl fumarate, the single-tablet regimens of emtricitabine/rilpivirine/tenofovir disoproxyl fumarate and efavirenz/emtricitabine/tenofovir disoproxyl fumarate, ritonavir-boosted HIV protease inhibitors Darunavir and Atazanavir, and raltegravir are among the commonly used antiretrovirals evaluated in drug interaction studies. [source, 2015]
Today, Ritonavir is administered at low subtherapeutic doses of 100 mg as a cART-boosting agent together with a second-generation PI, ie, atazanavir or Darunavir. [source, 2015]
The pharmacokinetic parameters of Darunavir following coadministration of once-daily Darunavir 800 mg with cobicistat 150 mg, either as single agents33 or as two candidate fixed-dose combinations (G003 and G004),34 were similar to those of Darunavir/ritonavir (800/100 mg) administered once daily, except for lower plasma Darunavir concentrations after 24 hours with Darunavir/cobicistat.23,24 [source, 2015]
If combined with antiretrovirals that have to be dose-adjusted in the event of renal impairment (eg, Darunavir, atazanavir), cobicistat should be stopped when the GFR falls below 70 mL/min. [source, 2015]
Additionally, a phase IIIb study demonstrated superiority of dolutegravir to ritonavir-boosted Darunavir when both were used in combination with fixed-dose dual NRTI combinations [9]. [source, 2015]
Darunavir with low-dose Ritonavir has demonstrated anti-retroviral efficacy and tolerability in clinical trials in a range of HIV-1-infected patients, and is approved for use in treatment-naïve and treatment-experienced patients in several countries [15]. [source, 2015]
Moreover, in patients with resistant viruses and few remaining treatment options, the combination of raltegravir, etravirine, and Darunavir with low-dose Ritonavir resulted in excellent virological outcomes in the AIDS and viral hepatitis (ANRS) 139 TRIO trial [16]. [source, 2015]
However, Sildenafil exposure was also markedly increased when coadministered with Darunavir plus low-dose Ritonavir (400/100 mg twice daily). [source, 2015]